EGFR and non-small cell lung carcinoma: A single-arm phase 2 trial (NCT01833572) explored the impact of neoadjuvant gefitinib—a first-generation EGFR-TKI—among EGFR-mutated, stage II to IIIA NSCLC patients [51].